E. Ohman J or Asset Management AB Makes New Investment in Abbott Laboratories $ABT

E. Ohman J or Asset Management AB purchased a new stake in shares of Abbott Laboratories (NYSE:ABT) during the fourth quarter, Holdings Channel.com reports. The firm purchased 61,637 shares of the healthcare product maker’s stock, valued at approximately $7,722,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Carr Financial Group Corp increased its position in shares of Abbott Laboratories by 2.0% in the 3rd quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker’s stock valued at $520,000 after acquiring an additional 76 shares during the period. Gemmer Asset Management LLC lifted its position in Abbott Laboratories by 2.9% during the 3rd quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock worth $368,000 after acquiring an additional 78 shares during the period. Global Financial Private Client LLC grew its stake in Abbott Laboratories by 3.3% during the 3rd quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker’s stock valued at $331,000 after purchasing an additional 79 shares during the last quarter. Citizens & Northern Corp increased its holdings in shares of Abbott Laboratories by 0.4% in the third quarter. Citizens & Northern Corp now owns 21,875 shares of the healthcare product maker’s stock valued at $2,930,000 after purchasing an additional 79 shares during the period. Finally, American National Bank of Texas increased its holdings in shares of Abbott Laboratories by 2.4% in the fourth quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock valued at $427,000 after purchasing an additional 79 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Daniel J. Starks acquired 10,000 shares of the firm’s stock in a transaction on Wednesday, February 4th. The stock was acquired at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the completion of the transaction, the director owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. The trade was a 0.15% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the sale, the executive vice president owned 146,377 shares in the company, valued at $16,918,253.66. This trade represents a 0.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,055 shares of company stock valued at $353,097 in the last ninety days. Company insiders own 0.46% of the company’s stock.

Wall Street Analyst Weigh In

ABT has been the subject of a number of research reports. Oppenheimer decreased their target price on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Weiss Ratings lowered shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 26th. Citigroup decreased their price objective on shares of Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating for the company in a research note on Wednesday, March 11th. Argus cut their price objective on shares of Abbott Laboratories from $150.00 to $140.00 in a research note on Tuesday, January 27th. Finally, Leerink Partners reduced their target price on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a report on Friday, January 30th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $136.16.

Abbott Laboratories Stock Down 0.6%

Shares of ABT stock opened at $104.87 on Tuesday. Abbott Laboratories has a twelve month low of $104.10 and a twelve month high of $139.06. The stock has a market cap of $182.65 billion, a P/E ratio of 28.19, a P/E/G ratio of 1.68 and a beta of 0.74. The stock has a 50 day moving average of $112.36 and a 200 day moving average of $122.77. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. The business had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, sell-side analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.4%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.74%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.